• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lyra Therapeutics Inc. (Amendment)

    2/14/24 4:51:41 PM ET
    $LYRA
    Medical/Dental Instruments
    Health Care
    Get the next $LYRA alert in real time by email
    SC 13G/A 1 tm243309d20_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Lyra Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    55234L105

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO. 55234L105  Page 2 of 7

     

    CUSIP No.  55234L105
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,752,324
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,752,324
    (9) Aggregate amount beneficially owned by each reporting person 4,752,324
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.9%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO. 55234L105  Page 3 of 7

     

    CUSIP No.  55234L105
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,752,324
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,752,324
    (9) Aggregate amount beneficially owned by each reporting person 4,752,324
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.9%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO. 55234L105  Page 4 of 7

     

    CUSIP No.  55234L105
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,752,324
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,752,324
    (9) Aggregate amount beneficially owned by each reporting person 4,752,324
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 8.9%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      Lyra Therapeutics, Inc. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      480 ARSENAL WAY WATERTOWN, MA 02472
       
    Item 2(a). Name of Person Filing
       
      Nantahala Capital Management, LLC (“Nantahala”)
    Wilmot B. Harkey
    Daniel Mack (together the “Reporting Persons”)
       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
      130 Main St. 2nd Floor
    New Canaan, CT 06840  
       
    Item 2(c). Citizenship:
       
      Nantahala is a Massachusetts limited liability company.
    Each of Messrs. Harkey and Mack is a citizen of the United States of America.
       
    Item 2(d). Title of Class of Securities:  
       
      Common Stock, $0.001 par value per share (the “Shares”).  

     

     

     

     

    CUSIP NO. 55234L105  Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    55234L105

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

       
    Item 4. Ownership:
       
    Item 4(a). Amount Beneficially Owned:  
       
      As of December 31, 2023, Nantahala may be deemed to be the beneficial owner of 4,752,324 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares. The 4,752,324 Shares includes 702,106 Shares which may be acquired by the Reporting Persons within sixty days through the exercise of warrants.
       
    Item 4(b). Percent of Class:  
       
      As of December 31, 2023, each of the Reporting Persons may be deemed to be the beneficial owner of 8.9% of the total number of Shares outstanding (based upon information provided by the Issuer on Form 10-Q filed November 7, 2023, there were 52,563,127 Shares outstanding in addition to the 702,106 Shares issuable upon the exercise of the warrants).

     

     

     

     

    CUSIP NO. 55234L105  Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 4,752,324
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 4,752,324
     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 4,752,324
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 4,752,324
    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).

     

    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       
     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO. 55234L105  Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Taki Vasilakis
      Taki Vasilakis
      Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $LYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LYRA

    DatePrice TargetRatingAnalyst
    5/7/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    5/7/2024$10.00 → $0.50Buy → Hold
    Jefferies
    5/7/2024Buy → Underperform
    BofA Securities
    5/6/2024Outperform → Mkt Perform
    William Blair
    10/6/2023$15.00Buy
    BTIG Research
    8/31/2023$12.00Buy
    H.C. Wainwright
    5/24/2022$15.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $LYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lyra Therapeutics Inc.

      SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      12/16/24 9:02:59 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 7:48:39 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lyra Therapeutics Inc.

      SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)

      11/14/24 5:49:14 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase  WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --  Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up

      11/12/24 4:01:58 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

      -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN

      10/15/24 7:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    SEC Filings

    See more
    • Lyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      6/2/25 7:22:40 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Lyra Therapeutics Inc.

      8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/19/25 4:31:28 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Lyra Therapeutics Inc.

      DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)

      5/9/25 4:10:16 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lyra Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

      5/7/24 6:26:06 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously

      5/7/24 6:25:25 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • Lyra Therapeutics downgraded by BofA Securities

      BofA Securities downgraded Lyra Therapeutics from Buy to Underperform

      5/7/24 6:25:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Waksal Harlan bought $74,095 worth of shares (25,000 units at $2.96), increasing direct ownership by 11% to 261,966 units (SEC Form 4)

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      11/13/23 5:29:27 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Snyderman Nancy Lynn Md

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:31 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Smith W Bradford

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:30 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Merrifield C Ann

      4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)

      5/16/25 4:30:45 PM ET
      $LYRA
      Medical/Dental Instruments
      Health Care

    $LYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Incendia Therapeutics Appoints Bradford Smith as Chief Financial Officer

      Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies

      12/3/24 8:00:00 AM ET
      $LYRA
      Medical/Dental Instruments
      Health Care